Post Profile






Greater patient selection may be needed for 1st line nivolumab to improve progression-free survival

(European Society for Medical Oncology) Greater patient selection may be needed for first line nivolumab to improve progression-free survival over chemotherapy in advanced lung cancer as the CheckMate 026 trial gave negative results in a broad group of patients expressing PD-L1 in their tumor cells. The findings were presented at the ESMO 2016 Congress in Copenhagen.
read more

share

Related Posts


Lung Cancer Vaccine Boosts Progression Free Survival

Health : Medical News Today

An experimental vaccine, called TG4010, given together with chemotherapy resulted in significantly more progression free survival in patients with advanced lung cancer compared to those on chemotherapy alone, researchers from the Un...

MEK inhibition in KRAS-mutant NSCLC did not improve survival

Diseases & Conditions / Cancer : EurekAlert: Cancer

(European Society for Medical Oncology) MEK inhibitor selumetinib in combination with docetaxel does not improve progression free or overall survival in individuals with KRAS-mutant non-small-cell lung cancer (NSCLC), according to d...

Nivolumab reduces symptoms in relapsed metastatic head and neck cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Nivolumab maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial presented at the ESMO 2016 Congres...

Nivolumab improves overall survival in patients with advanced kidney cancer: Results from the CheckMate 025 trial

Academics / General Science : ScienceDaily: Science Society

The targeted drug nivolumab significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, according to results to be presented at the 2015 European Cancer Congress...

Medical News Today: Study finds drug improves survival for patients with non-small cell lung cancer

Health : Medical News Today

A new phase 3 trial finds that overall survival is longer for patient with non-small cell lung cancer treated with the drug nivolumab compared with chemotherapy drug docetaxel.

Comments


Copyright © 2016 Regator, LLC